Research and consultancy, Tabbush Report

Daniel Tabbush

Research and consultancy

Tabbush Report

We provide research and consultancy on Asian banks. Our focus is on what we call “Asian bank research, without the noise.” We are interested in the most critical swing-factors for banks, the NPL and credit cycle, and where we believe there is a gap between perception and reality. We often focus on the less studied components of bank financial statements.  Our research is highly thematic, sometimes examining unlisted banks and companies as a window on mainstream banks. 

Being independent allows us to look at smaller banks, often overlooked by others. Analysis of BIS bank guidelines in the context of Asia, is also a focal point, while we also analyze global banks operating in the region. We use what we believe is the most comprehensive, reliable financials database, SNL Financial. S&P Capital IQ augments our database, with corporate data and CEIC, with economics. 

Asian bank research, without the noise.

Thematic (Sector/Industry)

<ul>
<li>New HDFC Bank appears to have far better returns and credit metrics that large Asian peers</li>
<li>Pro-Forma amalgamation puts HDFC Bank as 2nd largest bank in Asia Pacific in market cap </li>
<li>Comparably large banks in Asia are concentrated in China, where credit metrics are opaque</li>
</ul>


New HDFC Bank appears to have far better returns and credit metrics that large Asian peers
Pro-Forma amalgamation puts HDFC Bank as 2nd largest bank in Asia Pacific in market cap 
Comparably large banks in Asia are concentrated in China, where credit metrics are opaque


HDFC Bank - Ranks 2nd After Merger Compared With Asia Pacific Banks

Specialist in Indian Banking and Economic Research

Hemindra Hazari

<ul>
<li>Erstwhile Citibank India's retail customers are high-income, high spending and demand excellent customer service</li>
<li>In FY2022, as per the latest data, Axis Bank has the dubious distinction of becoming the customer complaints market leader in private sector banking</li>
<li>If Axis Bank does not improve its customer service, erstwhile Citibank's lucrative retail customers will flee to competitors</li>
</ul>


Erstwhile Citibank India's retail customers are high-income, high spending and demand excellent customer service
In FY2022, as per the latest data, Axis Bank has the dubious distinction of becoming the customer complaints market leader in private sector banking
If Axis Bank does not improve its customer service, erstwhile Citibank's lucrative retail customers will flee to competitors


Will Citi’s Retail Customers Stick with Axis Bank, the Private Sector Market Leader in Complaints?

<ul>
<li>Obnoxious video of bank official abusing staff for not meeting unrealistic sales targets</li>
<li>Issue is widely prevalent in the private sector financial system demonstrating poor leadership, communicational and motivational training</li>
<li>Setting aggressive sales target results in mis-selling, undermines confidence in the financial system and regulatory intervention may impact profitability.</li>
</ul>


Obnoxious video of bank official abusing staff for not meeting unrealistic sales targets
Issue is widely prevalent in the private sector financial system demonstrating poor leadership, communicational and motivational training
Setting aggressive sales target results in mis-selling, undermines confidence in the financial system and regulatory intervention may impact profitability.


Yet Another Instance of Toxic Work Culture in Private Sector Banks

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

National Stock Exchange of India / Equity Capital Markets

National Stock Exchange of India (NSE IN)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/national-stock-exchange" target="_blank" data-smartkarma-citation="entities:23751:1" rel="noopener">National Stock Exchange (NSEIN IN)</a> is looking to raise upto US$2.5bn in its India IPO.</li>
<li>NSE operates electronic platforms for trading equities, derivatives, currencies, and debt securities, also earning revenue from clearing and settlement services, market data, index licensing, listing fees, connectivity, and technology services.</li>
<li>We have looked at the company’s past performance in our previous note. In this note, we talk about valuations.</li>
</ul>



National Stock Exchange (NSEIN IN) is looking to raise upto US$2.5bn in its India IPO.
NSE operates electronic platforms for trading equities, derivatives, currencies, and debt securities, also earning revenue from clearing and settlement services, market data, index licensing, listing fees, connectivity, and technology services.
We have looked at the company’s past performance in our previous note. In this note, we talk about valuations.


Aequitas: NSE Pre-IPO - Thoughts on Valuations

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

Dr Agarwal's Health Care Ltd / Equity Capital Markets

Dr Agarwal's Health Care Ltd (8140044Z IN)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/dr-agarwal-s-health-care-ltd" target="_blank" data-smartkarma-citation="entities:43984:1" rel="noopener">Dr Agarwal's Health Care Ltd (8140044Z IN)</a> raised around US$350m in its India IPO in Jan 2025. The lockup on its pre-IPO investors is set to expire soon.</li>
<li>Dr Agarwal’s Health Care is a healthcare/hospital chain in India providing eyecare services, including surgeries; consultations, diagnoses, non-surgical treatments; and sells opticals, contact lens, accessories and eyecare related pharmaceutical products.</li>
<li>In this note, we will talk about the lockup dynamics and possible placement.</li>
</ul>



Dr Agarwal's Health Care Ltd (8140044Z IN) raised around US$350m in its India IPO in Jan 2025. The lockup on its pre-IPO investors is set to expire soon.
Dr Agarwal’s Health Care is a healthcare/hospital chain in India providing eyecare services, including surgeries; consultations, diagnoses, non-surgical treatments; and sells opticals, contact lens, accessories and eyecare related pharmaceutical products.
In this note, we will talk about the lockup dynamics and possible placement.


Dr Agarwal’s Health Care IPO Lockup - US$725m Lockup Release; PE Investors May Look to Cash Out

India

State Bank of India is a multinational public sector bank and financial services statutory body. It offers a comprehensive range of banking services, including retail, corporate, and investment banking, along with various financial products like loans, savings accounts, and wealth management. The bank is headquartered in Mumbai, India, and traces its origins back to the Bank of Calcutta, founded in 1806, eventually becoming State Bank of India on July 1, 1955.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

State Bank of India (SBID LI)

HDFC Bank - Ranks 2nd After Merger Compared With Asia Pacific Banks

The merger is now done, and this is more relevant, highlighting now large HDFC Bank is now in Asia Pacific, not only in India.

Daniel Tabbush

Will Citi’s Retail Customers Stick with Axis Bank, the Private Sector Market Leader in Complaints?

In the absence of any clarity from Axis Bank on the unprecedentedly high levels of customer complaints, retaining erstwhile Citibank's retail...

Hemindra Hazari

Yet Another Instance of Toxic Work Culture in Private Sector Banks

It would be naïve to believe that this incident is an anomaly. Banking can ill-afford the consequences of oppressed staff and reguires regulatory...

Hemindra Hazari

Aequitas: NSE Pre-IPO - Thoughts on Valuations

National Stock Exchange (NSEIN IN) is looking to raise upto US$2.5bn in its India IPO. In this note, we talk about valuations.

Sumeet Singh

Dr Agarwal’s Health Care IPO Lockup - US$725m Lockup Release; PE Investors May Look to Cash Out

TPG and Temasek are selling part of their stakes , around 11% of Dr Agarwal Health Care's existing share capital, to raise around US$183m, at a...

Akshat Shah

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)